LivaNova PLC (LIVN) shares are soaring 8.19% in pre-market trading on Wednesday following the release of its impressive second-quarter results and raised full-year guidance. The medical technology company reported strong performance across its key business segments, surpassing analyst expectations.

For the second quarter of 2025, LivaNova posted adjusted earnings per share of $1.05, significantly beating the consensus estimate of $0.86. Revenue for the quarter reached $352.5 million, marking a 10.7% increase year-over-year and surpassing the analyst expectations of $332.3 million. The company's Cardiopulmonary and Neuromodulation segments showed robust growth, driven by strong demand for consumables and the Essenz Perfusion System.

In light of the strong performance, LivaNova has raised its full-year 2025 guidance. The company now expects revenue growth between 8% and 9% on a constant-currency basis, up from the previous projection of 6% to 7%. Additionally, LivaNova increased its adjusted earnings per share forecast to a range of $3.70 to $3.80, reflecting growing confidence in its operational performance and market positioning. The raised outlook and beat on both top and bottom lines have clearly excited investors, leading to the significant stock price jump in pre-market trading.